ELAB
Price
$4.42
Change
-$0.13 (-2.86%)
Updated
Apr 3 closing price
Capitalization
2.63M
REGN
Price
$603.11
Change
-$7.54 (-1.23%)
Updated
Apr 4, 10:47 AM (EDT)
Capitalization
66.76B
25 days until earnings call
Ad is loading...

ELAB vs REGN

Header iconELAB vs REGN Comparison
Open Charts ELAB vs REGNBanner chart's image
PMGC Holdings
Price$4.42
Change-$0.13 (-2.86%)
Volume$30.04K
Capitalization2.63M
Regeneron Pharmaceuticals
Price$603.11
Change-$7.54 (-1.23%)
Volume$100
Capitalization66.76B
ELAB vs REGN Comparison Chart
Loading...
ELAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELAB vs. REGN commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAB is a Hold and REGN is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (ELAB: $4.42 vs. REGN: $610.64)
Brand notoriety: ELAB: Not notable vs. REGN: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ELAB: 14% vs. REGN: 111%
Market capitalization -- ELAB: $2.63M vs. REGN: $66.76B
ELAB [@Biotechnology] is valued at $2.63M. REGN’s [@Biotechnology] market capitalization is $66.76B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAB’s FA Score shows that 1 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s).

  • ELAB’s FA Score: 1 green, 4 red.
  • REGN’s FA Score: 1 green, 4 red.
According to our system of comparison, REGN is a better buy in the long-term than ELAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAB’s TA Score shows that 5 TA indicator(s) are bullish while REGN’s TA Score has 4 bullish TA indicator(s).

  • ELAB’s TA Score: 5 bullish, 3 bearish.
  • REGN’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ELAB is a better buy in the short-term than REGN.

Price Growth

ELAB (@Biotechnology) experienced а -9.43% price change this week, while REGN (@Biotechnology) price change was -3.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

REGN is expected to report earnings on Apr 29, 2025.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($66.8B) has a higher market cap than ELAB($2.63M). REGN YTD gains are higher at: -14.166 vs. ELAB (-72.427). REGN has higher annual earnings (EBITDA): 5.32B vs. ELAB (-4.75M). REGN has more cash in the bank: 9.01B vs. ELAB (6.43M). ELAB has less debt than REGN: ELAB (103K) vs REGN (2.7B). REGN has higher revenues than ELAB: REGN (14.2B) vs ELAB (2.45M).
ELABREGNELAB / REGN
Capitalization2.63M66.8B0%
EBITDA-4.75M5.32B-0%
Gain YTD-72.427-14.166511%
P/E RatioN/A15.93-
Revenue2.45M14.2B0%
Total Cash6.43M9.01B0%
Total Debt103K2.7B0%
FUNDAMENTALS RATINGS
REGN: Fundamental Ratings
REGN
OUTLOOK RATING
1..100
67
VALUATION
overvalued / fair valued / undervalued
1..100
3
Undervalued
PROFIT vs RISK RATING
1..100
75
SMR RATING
1..100
54
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
89
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ELABREGN
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
64%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
87%
Bullish Trend 1 day ago
66%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
60%
MACD
ODDS (%)
Bullish Trend 1 day ago
50%
Bearish Trend 1 day ago
53%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
56%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
64%
Advances
ODDS (%)
Bullish Trend 10 days ago
84%
Bullish Trend 26 days ago
61%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
53%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
49%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
59%
View a ticker or compare two or three
Ad is loading...
ELAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TW149.020.53
+0.36%
Tradeweb Markets
BRSP5.41-0.18
-3.22%
BrightSpire Capital
RDHL2.26-0.19
-7.76%
Redhill Biopharma Ltd
SFBS73.97-8.24
-10.02%
ServisFirst Bancshares
DXLG1.27-0.21
-14.43%
Destination XL Group

ELAB and

Correlation & Price change

A.I.dvisor tells us that ELAB and EPIX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ELAB and EPIX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAB
1D Price
Change %
ELAB100%
-2.86%
EPIX - ELAB
31%
Poorly correlated
N/A
LXRX - ELAB
25%
Poorly correlated
-11.91%
EDSA - ELAB
22%
Poorly correlated
-5.31%
ALLK - ELAB
21%
Poorly correlated
-0.40%
REGN - ELAB
20%
Poorly correlated
-2.39%
More